ATE349427T1 - Tryptaseinhibitoren - Google Patents

Tryptaseinhibitoren

Info

Publication number
ATE349427T1
ATE349427T1 AT02722097T AT02722097T ATE349427T1 AT E349427 T1 ATE349427 T1 AT E349427T1 AT 02722097 T AT02722097 T AT 02722097T AT 02722097 T AT02722097 T AT 02722097T AT E349427 T1 ATE349427 T1 AT E349427T1
Authority
AT
Austria
Prior art keywords
tryptase inhibitors
inhibitors
compounds
formula
tryptase
Prior art date
Application number
AT02722097T
Other languages
English (en)
Inventor
Thomas Martin
Thomas Baer
Josef Stadlwieser
Wolf-Ruediger Ulrich
Andreas Dominik
Daniela Bundschuh
Karl Zech
Christian P Sommerhoff
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of ATE349427T1 publication Critical patent/ATE349427T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicinal Preparation (AREA)
  • Luminescent Compositions (AREA)
  • Pyridine Compounds (AREA)
AT02722097T 2001-02-21 2002-02-19 Tryptaseinhibitoren ATE349427T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01104109 2001-02-21

Publications (1)

Publication Number Publication Date
ATE349427T1 true ATE349427T1 (de) 2007-01-15

Family

ID=8176550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02722097T ATE349427T1 (de) 2001-02-21 2002-02-19 Tryptaseinhibitoren

Country Status (9)

Country Link
US (1) US7060716B2 (de)
EP (1) EP1368317B1 (de)
JP (1) JP2004518736A (de)
AT (1) ATE349427T1 (de)
AU (1) AU2002253035B8 (de)
CA (1) CA2438685A1 (de)
DE (1) DE60217076T2 (de)
ES (1) ES2278913T3 (de)
WO (1) WO2002066430A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278928T3 (es) 2001-06-19 2007-08-16 Altana Pharma Ag Inhibidores de triptasa.
CN105209435B (zh) * 2013-05-14 2018-02-02 3M创新有限公司 包含吡啶或吡嗪的化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032945A1 (en) 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
KR970706267A (ko) 1994-09-23 1997-11-03 다니엘 에이치. 페트리 비만 세포 염증성 질환 치료용 조성물 및 방법(compositions and methods for treating mast-cell inflammatory condition)
AU733621B2 (en) 1996-07-30 2001-05-17 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating diseases associated with tryptase activity
AU8997498A (en) 1997-09-05 1999-03-29 Yoshitomi Pharmaceutical Industries, Ltd. Tryptase inhibitor
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
EP1030844A1 (de) 1997-11-10 2000-08-30 Array Biopharma Inc. Verbindungen, die die aktivität von tryptase hemmen
ES2233025T3 (es) 1998-02-06 2005-06-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Agente inhibidores de la triptasa.
EP1060171A2 (de) 1998-02-06 2000-12-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase-inhibitoren
DE19851299A1 (de) * 1998-02-06 1999-08-12 Max Planck Gesellschaft Tryptase-Inhibitoren
WO2000014097A2 (de) 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Neue pyranosen
JP2003506442A (ja) 1999-08-10 2003-02-18 アルタナ ファルマ アクチエンゲゼルシャフト 新規トリプターゼインヒビター
DE19937721A1 (de) 1999-08-10 2001-02-15 Max Planck Gesellschaft Neue Diketopiperazine
JP2003509417A (ja) 1999-09-14 2003-03-11 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼインヒビター
TR200402322T4 (tr) 1999-12-20 2004-12-21 Altana Pharma Ag Triptaz inhibitörler
JP2003518087A (ja) 1999-12-20 2003-06-03 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼインヒビター

Also Published As

Publication number Publication date
ES2278913T3 (es) 2007-08-16
US20040067943A1 (en) 2004-04-08
US7060716B2 (en) 2006-06-13
CA2438685A1 (en) 2002-08-29
DE60217076T2 (de) 2007-06-21
AU2002253035B2 (en) 2007-08-23
EP1368317A1 (de) 2003-12-10
JP2004518736A (ja) 2004-06-24
WO2002066430A1 (en) 2002-08-29
AU2002253035B8 (en) 2008-02-21
DE60217076D1 (en) 2007-02-08
EP1368317B1 (de) 2006-12-27

Similar Documents

Publication Publication Date Title
YU27304A (sh) Novi dihidropteridinoni, postupak za njihovo dobijanje i njihova primena kao lekova
ATE228111T1 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
NO20034660D0 (no) Spiropyrazolforbindelser
BR0111451A (pt) Inibidores de serina protease
NO20041493L (no) Kjemiske forbindelser.
ATE338461T1 (de) Pyrazolpyrimidinfungizide
SE0100903D0 (sv) Compounds
SE0004245D0 (sv) Novel compounds and their use
ATE372767T1 (de) Dpp-iv-hemmer
DE50202504D1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
ATE275544T1 (de) Serinprotease-inhibitoren
SE0103710D0 (sv) Compounds
EP1667976A4 (de) Isochinolinon-kaliumkanalinhibitoren
ATE287403T1 (de) 6-phenylbenzonaphthyidine
DK1204659T3 (da) Serotonerge benzofuraner
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
ATE269313T1 (de) Tryptase-inhibitoren
DK1244614T3 (da) Tryptase-inhibitorer
DE60217076D1 (en) Tryptaseinhibitoren
ATE343390T1 (de) Kalzilytische verbindungen
ATE364037T1 (de) Tryptasehemmer
ATE348803T1 (de) Tryptase-inhibitoren
NO20024679D0 (no) Krystallinsk farmasöytikum
DK1521752T3 (da) Makrocykliske forbindelser til behandling af cancer
DK1358182T3 (da) Diazocin-derivater og anvendelsen deraf som tryptase-inhibitorer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties